Tpharm.info


Velcade package insert





VELCADE (bortezomib) Official Website

12/21/2014
05:15 | Author: Kayla Henderson

Ambien package insert
VELCADE (bortezomib) Official Website

VELCADE (bortezomib) for the treatment of patients with mantle cell lymphoma (a cancer of the lymph nodes) who have relapsed, meaning return of signs and.

Hear real stories from people who have received treatment with VELCADE (bortezomib).

Before you receive treatment with VELCADE, l your doctor about all of your medical conditions. You should not receive VELCADE if you are allergic to bortezomib, boron, or mannitol.

VELCADE (bortezomib) is approved for the treatment of patients with multiple myeloma (a cancer of the plasma cells). VELCADE is also approved for the treatment of patients with mantle cell lymphoma (a cancer of the lymph nodes) who have already received other treatments.

VELCADE (bortezomib) can cause serious side effects, including:

More than 1 in 5 patients (20%) receiving VELCADE have experienced the following side effects: nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia (nerve pain), anemia, leukopenia (low levels of white blood cells), constipation, vomiting, lymphopenia (low levels of a certain type of white blood cells), rash, pyrexia (fever), and anorexia.

Questions to ask your healthcare team about your diagnosis and treatment.

VELCADE (bortezomib) for the treatment of patients with multiple myeloma (a cancer that starts in the plasma cells in bone marrow).

You should also l your doctor if you:

Please see the full Prescribing Information for VELCADE, including Warnings and Precautions.

VELCADE is prescribed by a physician experienced in the use of medications to treat cancer.

Comments (1)Read more



Velcade (Bortezomib) Drug Information Description, User Reviews

10/20/2014
03:30 | Author: David Perry

Fluzone package insert
Velcade (Bortezomib) Drug Information Description, User Reviews

Bortezomib is a modified dipeptidyl boronic acid. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester.

This drug may make you dizzy or cause vision changes. Do not.

Before using this medication, l your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as boron, mannitol), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, l your doctor or pharmacist your medical history, especially of: nerve sensation problems (e.g., peripheral neuropathy), heart disease, low blood pressure, loss of body fluids (dehydration), diabetes, liver disease, severe kidney disease, certain viral infection (herpes, shingles).

"The U.S.

Comments (2)Read more

Side Effects of Velcade (Bortezomib) Drug Center - RxList

8/19/2014
01:05 | Author: Kayla Henderson

Fluzone package insert
Side Effects of Velcade (Bortezomib) Drug Center - RxList

Find a comprehensive guide to possible side effects when taking Velcade (Bortezomib) for Professionals, Patients, and Caregivers.

The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

FDA Approves Pomalyst for Advanced Multiple Myeloma »

The safety data described below and in Table 10 reflect exposure to either VELCADE (n=331) or dexamethasone (n=332) in a study of patients with relapsed multiple myeloma. VELCADE was administered intravenously at doses of 1.3 mg/m² twice weekly for 2 out of 3 weeks (21-day cycle).

Comments (3)Read more

DrugBortezomib - Velcade Oncology - Intravenous Dilution Data

6/18/2014
01:20 | Author: David Perry

Fluzone package insert
DrugBortezomib - Velcade Oncology - Intravenous Dilution Data

The recommended dose of VELCADE is 1.3 mg/m2 administered as a 3 to 5 second bolus WARNINGS/PRECAUTIONS: See Package insert.

Comments (0)

VELCADE (Millennium Pharmaceuticals, Inc.) FDA Package Insert

4/17/2014
03:15 | Author: Kayla Henderson

Fluzone package insert
VELCADE (Millennium Pharmaceuticals, Inc.) FDA Package Insert

Millennium Pharmaceuticals, Inc.: VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment.

VELCADE — bortezomib injection, powder, lyophilized, for solution Millennium Pharmaceuticals, Inc.

Dose modifications guidelines for peripheral neuropathy are provided.

Fri, 17 Oct 2014. Injected particulate material may result in local inflammation, phlebitis, and/or low-level allergic response to the particulate or microembolic effects.

VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

Thu, 16 Oct 2014. September 2014 Drug Safety Labeling Changes includes 55 products with revisions to Prescribing Information.

This site complies with the HONcode standard for trustworthy health information: verify here.

When administered intravenously, VELCADE is administered as a 3 to 5 second bolus intravenous injection.

Comments (5)Read more